4.5 Article

Lycopene inhibits IL-1β-induced inflammation in mouse chondrocytes and mediates murine osteoarthritis

期刊

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
卷 25, 期 7, 页码 3573-3584

出版社

WILEY
DOI: 10.1111/jcmm.16443

关键词

lycopene; NF-kappa B; Nrf2/HO-1; osteoarthritis; STAT3

资金

  1. Wenzhou Municipal Science and Technology Bureau [Y20180027]

向作者/读者索取更多资源

The study demonstrated that Lycopene could inhibit the expression of inflammatory factors, alleviate the degradation of extracellular matrix, and activate the Nrf2/HO-1 pathway to reverse the activations of NF-kappa B and STAT3 signal pathway. The results suggest that Lycopene may be a promising novel drug for OA treatment as it could inhibit the occurrence and development of OA in mice.
Osteoarthritis (OA) is a common chronic degenerative condition in the elderly, in which inflammation plays a key role in disease pathology. Lycopene (Lye), a member of the carotenoid family, has been reported to have anti-inflammatory effects. The purpose of this study was to investigate the effect of Lye on the inflammation of chondrocytes and the mouse OA model. Chondrocytes were treated with interleukin (IL)-1 beta, and the mouse OA model was induced by the surgical destabilization of the medial meniscus (DMM). The results showed that Lye could inhibit the expression of inflammatory factors and alleviate the degradation of extracellular matrix (ECM). Additionally, Lye could activate the Nrf2/HO-1 pathway and reverse the activations of NF-kappa B and STAT3 signal pathway induced by IL-1 beta, suggesting that its anti-inflammatory effect may be mediated via these pathways. The animal experiments showed that Lye could decrease the Osteoarthritis Research Society International (OARSI) scores of the knee, indicating that it could inhibit the occurrence and development of OA in mouse. Overall, our results indicated that Lye might be used as a novel drug for OA treatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据